RCMI Coordinating Center (RCMI CC) Header Logo

Edna M. Mora Piñero

Concepts (73)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cell-Derived Microparticles
1
2015
7
0.550
Why?
Biological Specimen Banks
1
2015
25
0.530
Why?
Exosomes
1
2015
101
0.480
Why?
Ascorbic Acid
5
2005
66
0.280
Why?
RNA, Small Interfering
4
2012
409
0.260
Why?
Ovarian Neoplasms
3
2015
312
0.250
Why?
Drug Delivery Systems
3
2011
202
0.190
Why?
Chitosan
2
2011
36
0.190
Why?
Neoplasms
5
2011
1103
0.140
Why?
Antioxidants
3
2005
416
0.140
Why?
Nanoparticles
2
2011
318
0.140
Why?
Gene Silencing
3
2011
151
0.140
Why?
Receptor, EphB4
1
2015
3
0.130
Why?
Erythropoietin
1
2015
39
0.130
Why?
Breast Neoplasms
3
2015
1502
0.130
Why?
Neoplasms, Glandular and Epithelial
1
2012
40
0.100
Why?
Mice, Nude
4
2015
337
0.100
Why?
Hydrogels
1
2011
37
0.100
Why?
Lipoproteins, HDL
1
2011
46
0.090
Why?
Cell Cycle Proteins
1
2012
229
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2015
807
0.090
Why?
Melanoma
1
2011
96
0.090
Why?
Oligopeptides
1
2010
102
0.090
Why?
Animals
6
2015
15081
0.080
Why?
Antineoplastic Agents
4
2011
803
0.070
Why?
Cell Line, Tumor
4
2015
2231
0.070
Why?
Humans
11
2015
37093
0.060
Why?
Orthomolecular Therapy
1
2002
3
0.050
Why?
Copper Sulfate
1
2002
5
0.050
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2015
623
0.050
Why?
Blotting, Western
2
2015
859
0.050
Why?
Mice
4
2012
5913
0.050
Why?
Xenograft Model Antitumor Assays
2
2011
259
0.040
Why?
Female
6
2015
20969
0.040
Why?
Receptors, Erythropoietin
1
2015
7
0.030
Why?
STAT3 Transcription Factor
1
2015
90
0.030
Why?
Infusions, Intravenous
2
2005
47
0.030
Why?
Recombinant Proteins
1
2015
515
0.030
Why?
Injections, Intravenous
2
2004
62
0.030
Why?
Disease Progression
1
2015
601
0.030
Why?
Protein Binding
1
2015
972
0.030
Why?
Vascular Endothelial Growth Factor A
1
2012
161
0.020
Why?
Neoplasm Invasiveness
1
2012
251
0.020
Why?
HCT116 Cells
1
2011
35
0.020
Why?
Dose-Response Relationship, Drug
2
2005
1039
0.020
Why?
Microspheres
1
2011
49
0.020
Why?
Mice, Inbred C57BL
1
2015
1609
0.020
Why?
Neoplasm Metastasis
1
2011
219
0.020
Why?
Receptors, Cell Surface
1
2010
144
0.020
Why?
Aged, 80 and over
1
2015
2379
0.020
Why?
Aged
2
2015
6741
0.020
Why?
Neoplasm Proteins
1
2010
213
0.020
Why?
RNA, Messenger
1
2012
1207
0.020
Why?
Models, Biological
1
2011
677
0.020
Why?
Middle Aged
2
2015
10129
0.020
Why?
Cell Proliferation
1
2011
1198
0.020
Why?
Young Adult
1
2015
4268
0.020
Why?
Palliative Care
1
2005
49
0.020
Why?
Combined Modality Therapy
1
2005
148
0.020
Why?
Clinical Protocols
1
2003
36
0.010
Why?
Virus Diseases
1
2003
22
0.010
Why?
Clinical Trials as Topic
1
2005
204
0.010
Why?
Bacterial Infections
1
2003
43
0.010
Why?
Drug Resistance, Neoplasm
1
2005
222
0.010
Why?
Anti-Infective Agents
1
2003
64
0.010
Why?
Neoplastic Stem Cells
1
2003
78
0.010
Why?
Pain
1
2005
251
0.010
Why?
Drug Screening Assays, Antitumor
1
2002
113
0.010
Why?
Cell Division
1
2002
307
0.010
Why?
Tumor Cells, Cultured
1
2002
502
0.010
Why?
Treatment Outcome
1
2004
1369
0.010
Why?
Adult
1
2015
11712
0.010
Why?
Male
1
2004
20025
0.000
Why?
Mora Piñero's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (73)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support